title: Phase II evaluation of Ly156758 in metastatic breast cancer.
abstract: Fourteen patients with disseminated breast cancer with primary or secondary resistance to tamoxifen were treated with LY156758. There were no complete or partial responses and 1 patient showed a minor response. These data illustrate that LY156758 did not have significant antitumor activity in patients previously treated with tamoxifen therapy.
authors.affiliation: Department of Medical Oncology, University of Texas M.D. Anderson Hospital and Tumor Institute, Houston.
authors.forename: A U
authors.initials: AU
authors.lastname: Buzdar
authors.forename: C
authors.initials: C
authors.lastname: Marcus
authors.forename: F
authors.initials: F
authors.lastname: Holmes
authors.forename: V
authors.initials: V
authors.lastname: Hug
authors.forename: G
authors.initials: G
authors.lastname: Hortobagyi
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D010880:Piperidines / Q000627:therapeutic use*; D020849:Raloxifene Hydrochloride
chemical_list: D004965:Estrogen Antagonists; D010880:Piperidines; D020849:Raloxifene Hydrochloride